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Interaction between Mutant Ataxin-1 and PQBP-1
Affects Transcription and Cell Death
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provides a basis for their deleterious, cell-specific ef- centrated at the periphery of these inclusions (Figure
1E, bottom right). Although unlabeled ataxin-1 was usedfects. We initially proposed this hypothesis when de-
scribing the differential activation of identical promoters in this experiment, the center of these inclusions was
also green, indicating that mutant ataxin-1 sequesteredby POU transcription factors (Okazawa et al., 1996b). We
suggested that cofactors that bind to the polyglutamine PQBP-1 into its core. Interestingly, pure inclusions of
PQBP1-YFP (small, dense inclusions) were often juxta-tract of a POU transcription factor could regulate its
activity. Such cofactors could also bind polyglutamine posed to nucleoli (the large patches in the right-hand
images).tracts in neurodegenerative disease gene products to
promote disease progression. Based on that rationale,
we cloned the PQBP-1 gene whose protein product PQBP-1 Interacts with Ataxin-1
binds to expanded polyglutamine tracts, as well as to Western blotting (WB) of human and mouse brain sam-
the neuronal transcription factor Brn-2 (Waragai et al., ples, using a polyclonal antibody against a carboxyl-
1999). PQBP-1 is expressed predominantly in the cere- terminal peptide of PQBP-1 (C2), revealed a single
bellum and functions as a repressive transcription co- band of about 35 kDa (Figure 2A). The intensity of this
factor of Brn-2. Furthermore, PQBP-1 forms nuclear in- band was higher in blots of a stable transfectant of
clusions (Zhang et al., 2000; Okazawa et al., 2001). These PQBP-1 (S7) (Waragai et al., 1999) than in parental cells
observations prompted us to test the involvement of (P19), suggesting that this species corresponds to
PQBP-1 in the pathology of polyglutamine diseases. In PQBP-1. In proliferating cells,C2 stained multiple high-
this study, we report that interaction between mutant molecular weight proteins (Figure 2A). Costaining with
ataxin-1 and PQBP-1 modifies transcription and induces an anti-ubiquitin antibody showed that these were poly-
cell death. ubiquitinated forms of PQBP-1 (data not shown). Faint
bands of low-molecular weight could represent alterna-
tive transcripts (Iwamoto et al., 2000) or degradationResults
products (Figure 1A).
To test the interaction between PQBP-1 and ataxin-1,PQBP-1 Colocalizes with Ataxin-1 in Nuclear
we transiently expressed ataxin-1 with either 30 or 82Inclusion Bodies
glutamine repeats (AT30 or AT82, respectively) in S7We investigated the morphological relationship between
cells. Immunoprecipitation (IP) with anti-ataxin-1 (AT1)ataxin-1 and PQBP-1 in 293 cells transfected with differ-
antiserum (Servadio et al., 1995) showed that PQBP-1ent fluorescent reporters (Rich et al., 1999). As reported
interacts with ataxin-1 predominantly in the nuclear frac-previously (Zhang et al., 2000; Okazawa et al., 2001),
tion (Figure 2B, left panel). The major coprecipitate wasPQBP-1 forms nuclear inclusion bodies. PQBP1-EGFP,
a 35 kDa species. Interaction with this protein correlatedcontaining full-length PQBP-1, aggregates into large nu-
positively with the length of the polyglutamine tract (Fig-clear inclusions, in addition to diffuse nucleoplasmic
ure 2B, right) and was corroborated by reverse IP (Figureexpression (Figure 1A). PQBP-1 inclusions comprise
2C). PQBP-1/ataxin-1 binding was also assayed by co-nonfluorescent core(s) similar to those reported for the
IP experiments using normal and ataxin-1 transgenicandrogen receptor and proteins that express acidic-
mice. In this case, only mutant ataxin-1 coprecipitatedbasic polar zippers (Stenoien et al., 1999; Rich et al.,
with PQBP-1 (Figure 2D). The discrepancy between this1999). Denser inclusions of PQBP-1 were also abundant.
and earlier data obtained with cell lines may be due toSerial sections of a red fluorescence fusion of PQBP-1
the different expression levels of PQBP-1 in mouse brain(PQBP1-RFP) clearly revealed the vesicular structure of
versus PQBP-1-stable transfectants.these inclusions (Figure 1B). Aggregates of PQBP1-RFP
To identify the domain that interacts with the polyglu-and mutant ataxin-1-GFP frequently colocalized to form
tamine sequence, we performed two-hybrid deletionheterotypic inclusions that comprised a core of ataxin-1
analyses. Bait vectors containing various PQBP-1 con-coated with PQBP-1 (Figures 1C and 1D). This suggests
structs were cotransfected with the polyglutamine tractthe propensity of ataxin-1 to seed inclusions and, at the
of ataxin-1 (Figure 2E). Interaction between AT82 andsame time, to alter the distribution of third-party proteins.
PQBP-1 was abrogated by deletion of the polar aminoThe reverse type of coaggregate with a PQBP-1 core was
acid-rich domain (PRD) of PQBP-1 (Figure 2E). To con-extremely rare.
firm this, we performed co-IP of S7 cells transfectedTransient transfection of 293 cells with PQBP1-YFP
with AT82 and a full-length fusion of PQBP-1 (PQBP1-and mutant ataxin-1 supported these findings (Figure
EGFP) or a truncate (PQBP1-EGFP) that lacks the PRD1E). To see how AT82 alters the distribution of PQBP-1,
to C-terminal segment (Figure 2F). Truncated PQBP-1we transfected PQBP-1-YFP both with and without unla-
failed to interact with ataxin-1 (Figure 2F). The C-terminalbeled AT82 (note that sections were scanned at an exci-
domain (CTD) of PQBP-1 is known to interact with U5-tation wavelength of 488 nM, which makes YFP appear
15 kDa (Waragai et al., 2000; Zhang et al., 2000). There-green). Coexpression of AT82 resulted in the formation
fore, we propose that the PRD, upstream of the CTD,of much larger, fainter inclusions (Figure 1E, bottom left),
may be essential for binding polyglutamines.indicating that mutant ataxin-1 accelerates inclusion
body formation of PQBP-1. To demarcate the margin of
each inclusion, images were transformed using an edge PQBP-1 Interacts with the CTD of RNA Polymerase II
Large Subunit Via the WW Domaineffect algorithm, which converts pixels to lines on an
arbitrary background (Figure 1E, right). This function We suspected that PQBP-1 may interact with the C-ter-
minal domain of RNA polymerase II large subunit (Polallowed us to size large, heterotypic inclusions of mutant
ataxin-1 and PQBP-1 (Figure 1D). PQBP1-YFP was con- II-CTD). This is because WW-containing proteins, such
Pol II Inhibition by Ataxin-1 and PQBP-1
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Figure 1. PQBP-1 Forms Nuclear Inclusions
(A) High-resolution confocal microscopy of a
293 cell nucleus transfected with PQBP1-EGFP
showed multiple nuclear inclusion bodies.
(B) Vesicular structure of PQBP1-RFP inclu-
sions.
(C) Single section of 293 cells coexpressing
mutant ataxin1-GFP (green) and PQBP1-RFP
(red), showing colocalization of these pro-
teins (arrow). In this type of mixed inclusion
body, a PQBP-1 capsule surrounds the
ataxin-1 core (arrow).
(D) Higher magnification of the heterotypic
inclusion showing that PQBP1-RFP envelops
ataxin-1-GFP.
(E) 293 cells transiently transfected with
PQBP1-YFP (top) and PQBP1-YFP and mu-
tant ataxin-1 (bottom). On the left-hand side
are single optical sections obtained using a
Leica TCS-NT laser scanning confocal micro-
scope. Images were captured at a resolution
1024 1024 and averaged four times. On the
right-hand side are the same images treated
using an edge effect algorithm to demarcate
PQBP-1 and PQBP-1/AT82 inclusions. This
algorithm converts pixels to lines on a single
color background. The upper two panels
(PQBP1-YFP) show small, condensed PQBP-1
inclusions. The lower two panels (PQBP1-
YFP  AT82) show larger but fainter hetero-
typic inclusions. The cores, comprising unla-
beled ataxin-1, appear green as they sequester
the labeled PQBP-1 protein.
as Prp40, Rsp5, and Pin1, interact both physically and creased when a specific CTD sequence (YSPGS-
PAYSPKQ) was phosphorylated at the first serine (datafunctionally with Pol II-CTD and participate in RNA splic-
ing and/or the regulation of transcription (reviewed by not shown). This finding is of interest since the Pol II-
CTD functions in a phosphorylation-dependent mannerSudol and Hunter, 2000). Second, the phenotype of the
embryonic Drosophila Dim1 mutant (whose product as- as a platform for multiple nucleoproteins that regulate
transcription and RNA modification (reviewed by Hirosesociates with PQBP-1) is similar to that observed when
RNA polymerase II activity is lost (Zhang et al., 2000). and Manley, 2000). This result places PQBP-1 at the
interface between transcription and RNA modification.To test whether PQBP-1 binds Pol II-CTD, we performed
a filter binding assay (Chang et al., 2000; Zhang et al., To confirm the interaction of PQBP-1 with Pol II, we
performed pull-down analyses with GST-PQBP1-WW2000) in which an array of SPOT peptides, correspond-
ing to the CTD sequence, was probed with a radioactive fusions using HeLa nuclear extracts. Consistent with the
SPOT filter binding assays, the RNA Pol II large subunitfusion protein that expresses GST fused to the PQBP-1
WW domain (GST-PQBP1-WW). As expected, we ob- bound to GST fusions that contained the WW domain
of PQBP-1 (Figure 3A, bottom). The specificity of thisserved an interaction between selected CTD peptides
and GST-PQBP1-WW. Furthermore, the affinity was in- interaction was demonstrated by the failure of RNA Pol II
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Figure 2. PQBP-1 Interacts with Ataxin-1 in Cells and Cerebellar Tissues
(A) WB analysis with C2. Hu and Mo, human and mouse cerebellar tissues, respectively; HMWL, high-molecular weight ladder bands in cells;
T, total cell homogenate; N, nuclear fraction; and C, cytoplasmic fraction of P19 and S7 cells.
(B) Coprecipitation of PQBP-1 and ataxin-1. Nuclear (N) and cytoplasmic (C) fractions of S7 cells transiently expressing AT82 were precipitated
with AT1 then blotted with C2 (left). IP with normal rabbit serum (NRS) was performed as a control. WB with parallel samples showed equal
expression levels of AT82 (lower left). Interaction was stronger in S7 cells expressing AT82 than in cells expressing AT30 (right). NT, nontrans-
fected cells. Samples before IP were blotted with -AT1 (lower right).
(C) Interaction between PQBP-1 and ataxin-1 in reverse IP. The amounts of AT82 and PQBP-1 (35 kDa band) used for IP are shown in the
lower panels. H, immunoglobulin heavy chain.
(D) IP with cerebellar tissues of nontransgenic (NT) and AT1-transgenic (B05) mice with 82 repeats. Ataxin-1 coprecipitated with PQBP-1 (left,
arrow) and vice versa (right, arrow).
(E) Yeast two-hybrid deletion analyses. pEB202 containing truncated PQBP-1 cDNAs (top), pJG4-5 containing the polyglutamine tract of AT82,
and pSH18-34 plasmid were cotransfected into cells. Four independent colonies from HWU plates were assayed on HWU-Xgal and HWUL
plates (bottom).
(F) Structures of PQBP1-EGFP and PQBP1-EGFP (upper panel). Their coprecipitation was tested in P19 and S7 cells (lower panels) 12 hr
after transfection with AT82. Expression levels of AT82 and each fusion protein were verified.
Pol II Inhibition by Ataxin-1 and PQBP-1
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Figure 3. Interaction between PQBP-1 and RNA Polymerase II Large Subunit
(A) Interaction between the PQBP-1 WW domain and Pol II. Nuclear proteins were pulled down with GST-PQBP1 or GST-Pol II-CTD and
blotted with C2 or H14 antibodies. The upper and lower arrowheads in the silver stain are Pol II and NpwBP, respectively.
(B) Interaction between PQBP-1 and Pol II under stringent conditions.
(C) Interaction between PQBP-1 and Pol II in mouse cerebellar tissues. N, normal control mouse; T, B05 transgenic mouse. QM against QM,
a cofactor of c-Jun, was used as a control.
(D) AT82 enhances ternary complex formation. P19 cells transiently expressing AT82 and PQBP-1 were precipitated with AT1 8 hr post
transfection and blotted with anti-Pol II (H14) and C2 antibodies.
(E) Pol II was not coprecipitated with AT82 in the absence of PQBP-1. PQBP-1 protein was repressed by expressing the anti-sense PQBP-1
vector (pCI-rPQBP-1) in P19 cells, and IP was performed 8 hr after transfection.
to bind GST alone or GST-Pol II-CTD (Figure 3A, bottom). because GST-Pol II-CTD was not authentically phos-
phorylated and could not bind the WW domain ofInterestingly, in reciprocal assays, PQBP-1 did not bind
GST-Pol II-CTD (Figure 3A, middle). This is probably PQBP-1. This notion is supported by the failure of the
Neuron
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Figure 4. Ataxin-1/PQBP-1-Induced Cell Death
Is Dependent on Ternary Complex Formation
with RNA Polymerase II
(A) Percentage cell death of S7, S8, and S10
cells 24 hr post transfection with pCI, AT30,
and AT82. Effects of their transient expres-
sion with or without pCI-PQBP-1 in P19 cells
(P19 or P19, respectively) are also shown.
Single transfection of AT82 in P19 cells in-
duced cell death, although very weakly. Data
are shown as mean SD of four independent
experiments.
(B) Depletion of PQBP-1 represses AT82-
induced cell death. Transfection of sense
and anti-sense PQBP-1 expression vectors
(pCI-PQBP-1 and pCI-rPQBP-1) modified the
amount of PQBP-1 protein in P19 cells (upper
panel). AT82-induced cell death positively
correlates with PQBP-1 protein level (lower
panel). Percentage cell death was calculated
over four independent transfections.
(C) Truncated PQBP-1 inserts in pcDNA3.1()/
Myc-His vector.
(D) Expression levels of the mutant proteins in
S7 cells 12 hr after transfection. Cell extracts
were precipitated with anti-Myc antibody and
blotted with anti-His antibody. The shifted
band of M2 (asterisk) reacted with anti-ubi-
quitin antibody (data not shown).
(E) Percentage cell death was estimated in
P19 and S7 cells 48 hr after transfection. M4
and the full-length construct increased AT82-
induced cell death to a similar degree, sug-
gesting that the PQBP1-CTD is dispensable
for cell death. In contrast, M2 and M3 lacking
polar amino acid-rich sequences, totally or
partially suppressed cell death. WW showed
similar suppression.
H14 reagent, specific for phosphorylated Pol II-CTD cells transiently expressing AT82. Both PQBP-1 and Pol
II coprecipitated with mutant ataxin-1 (Figure 3D). Anti-(Gall et al., 1999), to recognize GST-Pol II-CTD (Figure
3A, bottom). We then confirmed the interaction between sense repression of PQBP-1 blocked coprecipitation of
Pol II with AT82 (Figure 3E). These findings indicateGST-PQBP1 and Pol II under more stringent conditions
(Figure 3B). that the ternary complex is formed by PQBP-1 in the
presence of mutant ataxin-1.We next examined the in vivo interaction between
PQBP-1 and RNA Pol II, using mouse cerebellar tissues.
IP clearly showed their interaction in the mutant-ataxin-1 Ternary Complex Formation Is Critical for Cell
Death Induction by Mutant Ataxin-1 and PQBP-1transgenic mouse (Figure 3C). More importantly, the
strength of interaction was markedly altered in trans- We tested the effect of ataxin-1/PQBP-1 interaction on
cell viability using ataxin-1/PQBP-1 double transfec-genic versus control animals (T versus N in Figure 3C).
Any interaction in normal mouse cerebellum could only tants. AT82 dramatically induced cell death of PQBP1-
transformed cell lines (S7, S8, and S10), while AT30 didbe detected using large amounts of protein and long
exposure times (data not shown). These data suggest not affect viability (Figure 4A). Furthermore, transient
coexpression of AT82 with PQBP-1 in P19 cells pro-that mutant ataxin-1 enhances the interaction between
PQBP-1 and Pol II. This possibility was tested using P19 voked an equivalent level of cell death (Figure 4A, P19).
Pol II Inhibition by Ataxin-1 and PQBP-1
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Figure 5. Coexpression of PQBP-1 and Mu-
tant Ataxin-1 Reduces Phosphorylated RNA
Polymerase II in the Nucleus
(A) PQBP1-YFP and AT82 were transiently ex-
pressed in 293 cells.
(B) The same field stained with H5, specific
for phosphorylated Pol II. Staining of phos-
phorylated Pol II was clearly weaker in
PQBP1-YFP-positive cells compared to neg-
ative cells. H5 is specific for the phosphoser-
ine 2 version of Pol II. Bar, 10 m.
(C) Merged image of another field showing
the same result. Bar, 10 m.
(D) WB with H5 showing reduction of phos-
phorylated Pol II in P19 double transfectants
of PQBP-1 and mutant ataxin-1 and in the
cerebellar cortex of mutant ataxin-1 trans-
genic mouse (B05) (top left). Total amounts
of Pol II detected by an anti-Pol II-C terminus
antibody (Santa Cruz) were constant (middle,
left). Four independent blots were quantified
by image analyzer (Molecular Imager, Bio-
rad), and summarized (right). Mean and SDs
are indicated. Values are relative to P19 and
NT (nontransgenic mice) after correction with
-actin. In both cases, the difference was sta-
tistically significant (p 	 0.001, ANOVA).
Cell death in the presence of AT82 alone was diminished death (Figures 3D and 3E). To ask which of these interac-
tions is critical for cell death, we constructed vectors(Figure 4A, P19). Genomic DNA analysis of dying cells
revealed ladder formation. Electron-microscopic analy- that express truncated PQBP-1 proteins fused to
C-terminal Myc and oligo-histidine tags (Figures 4C andsis showed chromatin condensation, nuclear fragmen-
tation, cytoplasmic vacuolation, and the rupture of cyto- 4D). We then observed how these mutants affected
AT82-induced cell death in S7 and P19 cells. Cell viabilityplasmic membranes (data not shown). These features
are consistent with a typical case of apoptosis. The in transfectants that express PQBP-1 without the CTD
(M4) or full-length PQBP-1 were comparable (Figure 4E).discrepancy between the effects of AT82 and AT30
could be explained by their differential affinities to This suggests that truncation of the CTD preserves the
effect of AT82 on cell death and that interaction ofPQBP-1. Similar analyses in 293 cells revealed a statisti-
cally significant promotion of cell death when mutant PQBP1-CTD with U5-15 kD may not be essential for cell
death. However, this point should be addressed further,ataxin-1 was coexpressed with PQBP-1 (data not
shown). as AT82 binding to the PRD may repress U5-15 kDa
function and induce a similar effect to M4. In contrast,To confirm that PQBP-1 is essential for this cell death,
we attempted to correlate expression levels of PQBP-1 the M2 and M3 constructs with partial or total PRD
deletions suppressed AT82-induced cell death. Sup-with cell viability. Using sense and anti-sense expres-
sion vectors, we altered the amount of PQBP-1 protein pression was more pronounced when the PRD was to-
tally eliminated. This indicates that interaction betweenin P19 cells (Figure 4B, left). Repression of PQBP-1
caused a marked inhibition of AT82-induced cell death PQBP-1 and AT82 is essential for cell death. The WWD/
Pol II interaction (in the absence of AT82) appears to(Figure 4B, right). Conversely, elevation of PQBP-1 ex-
pression promoted cell death. This relationship clearly have a dominant-negative effect on cell death. Deletion
of the WW domain (M1) resulted in the loss of any sup-supports the involvement of PQBP-1 in AT82-induced
cell death. Furthermore, abnormal cells frequently pos- pression of cell death. The mutant lacking the WW do-
main alone (WW) suppressed AT82-induced cell death,sessed inclusion-like structures (data not shown).
The WWD, PRD, and CTD domains of PQBP-1 bind indicating that the PQBP-1/Pol II interaction is essential
for cell death induction (Figure 4E). IP shows that WWto phosphorylated-Pol II, ataxin-1, and U5-15kD, re-
spectively. We have shown that PQBP-1, AT82, and Pol binds to AT82 (data not shown). Therefore, this construct
can compete with PQBP-1 for AT82 and, in doing so,II form a ternary complex prior to AT82-induced cell
Neuron
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crease in protein (Figure 5D), indicating that it is only the
level of the phosphorylated species that is decreased.
Collectively, interaction of PQBP-1, ataxin-1, and Pol
II seem to induce either degradation or dephosphoryla-
tion of Pol II. SPOT analysis shows that PQBP-1 binds
predominantly to the phosphorylated form of Pol II. Con-
sequently, PQBP-1 might bridge Pol II with U5-15 kDa
in a phosphorylation-dependent manner, bringing to-
gether transcription and RNA modification (reviewed by
Hirose and Manley, 2000). This complex, abnormally
stabilized by mutant ataxin-1, must be degraded or se-
questered to preserve its normal physiologic function.
Alternatively, dephosphorylation might dissociate the
abnormal complex from Pol II-CTD. Although not con-
clusive, the relatively constant expression of total Pol II
(Figure 5D) supports the latter hypothesis.
PQBP-1 and Mutant Ataxin-1 Act Cooperatively
to Repress Transcription
As PQBP-1 interacts with CTD-Pol II and, together with
AT82, diminishes the level of phosporylated Pol II, we
Figure 6. PQBP-1 and Mutant Ataxin-1 Suppress Basal Transcrip- tested the effect of PQBP-1 and AT82 on basal transcrip-
tion Level Cooperatively tion. Initially, we assayed the effect of PQBP-1 on tran-
(A) PQBP-1 weakly suppressed basal transcription in P19 cells (left). scription using the pSV2-CAT reporter in P19 cells that
Coexpression of mutant ataxin-1 and PQBP-1 in P19 cells sup-
coexpress PQBP-1. PQBP-1 weakly suppressed tran-pressed basal transcription substantially (right). 5 g of reporter
scription in a dose-dependent manner (Figures 6A andplasmid (pSV2-CAT) was used.
6B). Interestingly, mutant, but not normal ataxin-1 en-(B) Relative CAT activity in each transfection. CAT activity in a single
transfection of the reporter plasmid was taken as 100%. The mean hanced the repressive effect of PQBP-1 on basal tran-
SD values are indicated (n 
 4). scription from the SV2 promoter (Figures 6A and 6B). It
(C) PQBP-1 lacking the PRD and CTD inhibited transcriptional is noteworthy that normal ataxin-1 repressed transcrip-
repression by PQBP-1 and AT82. 5 g of reporter plasmid (pSV2-
tion, as well as mutant, ataxin-1 when singly expressed.CAT) was used.
This suggests that PQBP-1 is crucial in relaying the
repressive effects of mutant ataxin-1. The PQBP-1
construct, which lacks the PRD and CTD sequences,
averts cell death. Cotransfection of these mutant inhibited transcriptional repression by PQBP-1 and
PQBP-1 vectors with AT82 into P19 cells, rather than AT82 (Figure 6C). This agrees with the dominant-nega-
S7, showed similar (though less marked) changes (Fig- tive effect of M2 (corresponding to PQBP-1) on AT82-
ure 4E). induced cell death (Figure 4E).
PQBP-1 Expression in Cerebellar NeuronsCoexpression of PQBP-1 and Mutant Ataxin-1
Reduces Levels of Phosphorylated RNA We then examined the involvement of PQBP-1 in the
region-specific neurodegeneration seen in SCA1 byPolymerase II
We next addressed the effect of mutant ataxin-1 and staining cerebellar tissues of a SCA1 patient with C2.
PQBP-1 surrounded nuclear inclusions of Purkinje cellsPQBP-1 on Pol II. An interaction between PQBP-1, Pol
II, and mutant ataxin-1 suggests that PQBP-1 may cose- and spread throughout the nuclear matrix while occa-
sionally condensing into nuclear body-like structures ingregate with Pol II into inclusions that inhibit Pol II func-
tion. Our preliminary observations did not show this. the control (Figure 7A). For unknown reasons, PQBP-1
expression in the nuclei of Purkinje cells was slightlyPol II was not incorporated into PQBP-1 inclusions but
remained in the nucleoplasm (data not shown). Even higher in the SCA1 patient than in the control (Figure
7A). Pol II was distributed homogeneously in the nucleithough ataxin-1 accelerates PQBP-1 incorporation into
inclusions, abundant PQBP-1 staining was still evident and was not sequestered to inclusions (Figure 7A).
These results were consistent with our previous data,in the nucleoplasm (Figure 1E).
Further experiments revealed that staining with the suggesting that PQBP-1-mediated cell death is relevant
to SCA1.H5 antibody, specific for phophorylated Pol II, was weak
in PQBP-1 transfectants (Figures 5A–5C). Elevated lev- We previously reported that PQBP-1 expression is
relatively high in the cerebellum (Waragai et al., 1999).els of PQBP-1 reduces the level of phosphorylated Pol
II protein. Masking of the antigenic site is unlikely as H5 To confirm this finding, we performed quantitative RT-
PCR on multiple regions of a normal human brain anddetects other phosphorylation sites on Pol II-CTD. Using
WB, we confirmed the decrease of phosphorylated Pol found that PQBP-1 expression is abundant in those re-
gions vulnerable to SCA1 (Figure 7B). We further exam-II in cells that express PQBP-1 and AT82, as well as
in the cerebellar cortex of mutant ataxin-1-transgenic ined this relationship by estimating PQBP-1 mRNA level
using quantitative PCR. PQBP-1 expression was highmouse (B05) (Figure 5D). WB with a pan-specific anti-
Pol II-C-teminus antibody did not reveal a dramatic de- in cerebellar cortex, medulla, and the anterior horn of
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Figure 7. PQBP-1 Expression in the Cerebellum
(A) Immunostaining of Purkinje cells with C2 and anti-phosphorylated Pol II (H14) antibodies. PQBP-1 expression was generally low in control
(Contl/PQBP-1). In SCA1, PQBP-1 stained the nucleoplasm and was distributed around nuclear inclusions (arrows, SCA1/PQBP-1). Pol II was
not sequestered to inclusions (SCA1/pol II) but located throughout the nuclear matrix both in control and SCA1 tissue (Contl/pol II and SCA1/
pol II). Pol II staining was stronger in the control. Similar results were obtained with H5 (data not shown).
(B) RT-PCR showing the expression of PQBP-1 in different human brain regions. The first two lanes were amplifications with neurofilament
primers after RNase treatment as a negative control. Asterisk denotes a nonspecific band.
(C) Profile of PQBP-1 expression in a normal human brain. The ratios between PQBP-1 and neurofilament light chain expression levels were
calculated from four independent samples, and the mean values  SD are shown. Brain regions frequently affected in SCA1 are indicated
with bold letters. Italics indicate regions that are generally spared.
the spinal cord but relatively low in cerebral cortex, the mutation show a wide variety of pathologies. In some
patients, the striatum and the autonomic nervous sys-posterior horn of the spinal cord, and basal ganglia,
such as caudate nucleus. Thus, the expression level tem (once said to be rarely affected) show neuronal loss
(Gilman et al., 1996). Consequently, the rather ubiquitousdirectly corresponds to the vulnerability of neurons in
SCA1 (Figure 7C). It is noteworthy that PQBP-1 expres- expression of PQBP-1 in the brain does not contradict
the SCA1 pathology. Considered together with the mainsion was low but detectable in disease-free tissues. It
is already known that patients carrying the SCA1 gene conclusions of this study, high expression of PQBP-1
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alternative pathology in which a preinclusion form of
polyglutamine disturbs transcription. Both inclusion-
dependent and -independent processes might be in-
volved in the pathology of polyglutamine diseases.
Furthermore, we describe physiologic functions of
PQBP-1. First, PQBP-1 binds to Pol II-CTD in a phos-
phorylation-dependent manner. Second, abnormal en-
hancement of this interaction (by mutant ataxin-1) re-
duces levels of the active form (phosphorylated form)
of Pol II. The feedback effect of PQBP-1 is of interest
as transcription and RNA modifications are linked via
phosphorylation of Pol II-CTD (Hirose and Manley,Figure 8. A Hypothetical Scheme of Transcriptional Repression by
2000), and the interaction with Pol II and U5-15 kD (Reu-Mutant Ataxin-1 and PQBP-1
ter et al., 1999; Berry and Gould, 1997; Waragai et al.,Mutant ataxin-1 increases the affinity of PQBP-1 for the phosphory-
2000; Zhang et al., 2000;) places PQBP-1 as a bridgelated and active form of Pol II, leading to its suppression and tran-
scriptional repression. between transcription and splicing. In support of this
idea, PQBP-1 interacts with another RNA binding pro-
tein, NpwBP (Komuro et al., 1999a,1999b). Taking this
hypothesis further, the feedback effect on the phosphor-appears to promote mutant ataxin-1-induced cell death,
ylation of the Pol II-CTD suggests that any interactionand the difference between endogenous PQBP-1 expres-
between PQBP-1 and Pol II may be transient during thesion levels may explain region-specific neurodegener-
switch between transcription and splicing.ation.
PQBP-1 possesses RD/RE repeats that are shared by
other proteins that interact with polyglutamine diseaseDiscussion
gene products (Rich et al., 1999; Yanagisawa et al.,
2000). These repeats are found in RD, the prototypicIn this study, we describe the promotion of cell death
RD/RE repeat protein (which is a component of the NELFby an interaction between mutant ataxin-1 and PQBP-1.
complex that represses RNA polymerase II elongation)
As a possible underlying mechanism, we found that this
(Yamaguchi et al., 1999). As RNA elongation is depen-
interaction reduces levels of phosphorylated Pol II in the
dent on phosphorylation of the Pol II-CTD (reviewed
nucleus and substantially represses basal transcription by Hirose and Manley, 2000), the repression of basal
(Figure 8). Many reports have implicated transcription transcription by PQBP-1 that we describe may be rele-
in polyglutamine diseases. CREB binding protein (CBP) vant to RNA elongation. Interestingly, the Orr laboratory
was reported to coaggregate with androgen receptor, has reported a direct interaction between ataxin-1 and
huntingtin, and atrophin-1/DRPLA gene product (Kazan- RNA, the strength of which inversely correlates with
tsev et al., 1999; McCampbell et al., 2000). Steffan et al. the length of polyglutamine repeat (Yue et al., 2001).
(2000) described that mutant huntingtin interacts with Ataxin-2 interacts with an RNA binding protein (Shibata
CBP and p53 to repress transcription. This group also et al., 2000), and both ataxin-1 and NpwBP bind poly-G
determined the domain of CBP that binds huntingtin RNA sequences (Komuro et al., 1999; Yue et al., 2001).
and found a reduction of the histone acetyltransferase These findings suggest the involvement of RNA elonga-
activity (Steffan et al., 2001). Shimohata et al. (2000) tion in polyglutamine diseases.
reported that interaction of expanded polyglutamine Transcription factors targeted by polyglutamine dis-
tracts with TAFII130 disturbs CREB-dependent tran- eases involve CBP, p53, TAFII130, and PQBP-1. Pertur-
scription, and Diamond et al. (2000) reported that the bation of their function could explain the change of gene
glucocorticoid receptor influences aggregation. Other expression in diseased brain tissue (Lin et al., 2000;
transcription cofactors have also been reported to inter- Fernandez-Funez et al., 2000). However, it is unclear
act with the polyglutamine disease gene products (Bou- why specific types of neurons are affected. Our results
tell et al., 1999; Hsiao et al., 1999). Furthermore, in addi- show that PQBP-1 is differentially distributed in the brain
tion to the initial breakthrough that implicated the and is higher in regions vulnerable to SCA1. Of course,
androgen receptor in Kennedy’s disease (La Spada et this distribution would appear to rule out its involvement
al., 1991), a neurological syndrome characterized by in polyglutamine diseases that affect other regions of the
marked cerebellar degeneration with a polyglutamine brain. Presently, we are generating PQBP-1 transgenic
repeat expansion in the TATA binding protein gene has mice to investigate these possibilities. This study adds
now been reported (Koide et al., 1999). Clearly, our re- a novel candidate to the list of molecules implicated in
sults support the functional link between polyglutamine SCA1 (Lin et al., 2000; Davidson et al., 2000; Fernandez-
Funez et al., 2000). Reconstruction of the pathology us-diseases and transcription.
ing these molecules may lead to a more complete under-An important conclusion of this study is that the inter-
standing of SCA1, which in turn will shed a light on theaction between PQBP-1 and mutant ataxin-1 reduced
pathogenesis of polyglutamine diseases.the phosphorylated form of Pol II. A recent report sug-
gested that sequestration of CBP into inclusion bodies
Experimental Proceduresunderlies transcriptional repression and cell death (Nu-
cifora et al., 2001). Meanwhile, the ternary complex did Antibodies against PQBP-1
not sequester Pol II into inclusion bodies but reduced C2 was raised against the C-terminal region of PQBP-1 by immu-
nizing a rabbit with the peptide C-VLRANAEASRTKQQD (aminolevels of the active species. This study suggests an
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acids 251–265) conjugated to the carrier protein by cysteine. Speci- mid. The product was subcloned as an EcoRI/XhoI fragment. This
construct does not contain 5-untranslated sequence. For GST-ficity of the antibody in WB and immunohistochemistry was recon-
firmed by preabsorption with GST-PQBP1 (data not shown). PQBP1-WW, a partial cDNA was amplified with F:AAAGGATCCGAT
CCTGTGGACTACGAGA and R:AAAGAATTCCGCTTCTGAGCTTC
TTGGC. The resultant protein encodes aa 36–94 of PQBP-1. Con-Ataxin-1 Expression Vectors
struction of GST-Pol II-CTD containing the CTD of the RNA polymer-Full-length ataxin-1 cDNAs with either 30 or 82 CAG repeats (Orr et
ase II large subunit was described previously (Chang et al., 2000).al., 1993; Banfi et al., 1994) were subcloned as EcoRI/SalI fragments
Each fusion protein (200 ng) was mixed with HeLa nuclear extractinto pBluescript SK, checked by sequencing, subcloned into a
(Dignam et al., 1983), incubated in NET buffer (40 mM Tris [pH 7.8],mammalian expression vector (pCIneo, Promega), and designated
100 mM KCl, 0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT, and 25%AT30 and AT82, respectively.
glycerol) for 1 hr at 4C, then pulled down with glutathione sepharose
4B (Pharmacia). The pellet was washed six times with NET bufferFluorescent Fusion Protein Expression Vectors
and extracted with Lammeli buffer.Construction of PQBP1-EGFP was described previously (Waragai
et al., 1999). For PQBP1-EGFP, the partial cDNA was amplified
with primers F:5-AAAGAATTCCTATGCCGCTGCCCGTTG-3 and
Expression Vectors of Deleted PQBP-1 ProteinsR:5-AAAGGATCCAACTTTTCTTCAGCATC-3 (corresponding to aa
Expression vectors (M1–M4) were constructed by subcloning inserts1–103 of PQBP-1) and subcloned into pEGFP-N1 (Clontech). Red
from pJGm1-m4 (Waragai et al., 1999) into pcDNA3.1()/Myc-Hisor yellow fluorescent fusion proteins were constructed by subclon-
vector (Invitrogen) between the EcoRI and BamHI sites. WW wasing the EcoRI/BamHI cDNA fragment from PQBP-1-EGFP (Waragai
constructed by subcloning a PCR fragment amplified with AAAGet al., 1999) into red or yellow fluorescent protein expression vectors
GATCCGACCCCAACTCCGTGGTT (nt 298 to 315 of AJ242829) and(Rich et al., 1999). Construction of ataxin-1-GFP, cotransfection into
AAAGGATCCATCCTGCTGCTTGGTTCG (nt 855 to 838) into the293 cells, and confocal microscopic analyses were performed as
BamHI site of the M1 vector. This construct comprises amino acidsdescribed previously (Rich et al., 1999).
1–45 then 80–265. S7 cells were transfected with AT82 and these
constructs. Expression levels for each mutant were verified by pre-Cell Death and Survival Assays in P19 and S7 Cells
cipitation with an anti-Myc antibody (Invirogen) and blotting withSense and anti-sense expression vectors of PQBP-1 (pCI-PQBP-1
anti-His antibody (Invitrogen).and pCI-rPQBP-1) were constructed by subcloning the full-length
cDNA (Waragai et al. 1999) between the EcoRI/SalI or EcoRI/XhoI
sites. 1  105 cells were plated on 10 cm culture grade dishes
Nested RT-PCR
(Corning) in -MEM medium (Sigma) with 10% fetal bovine serum.
RT-PCR was performed with total RNA prepared from normal human
12 hr later, 10 g of either pCIneo, AT30, or AT82 and 10 g of
brain tissues (Okazawa et al. 1996a). PQBP-1 and neurofilament
pBluescript-SK were transfected with Superfect (Qiagen) into stable
light chain partial cDNAs were amplified from 1 g total RNA of each
cells. 10 g of either pCIneo, AT30, or AT82 and 10 g of pCI-
brain region by using RT-PCR high kit (Toyobo) with the following
PQBP1-1 or pBluescript-SK were used for P19 or P19, respec-
primers. PQBP-1: ATGCCGCTGCCCGTTGCG and TGGCTCCGGTC
tively. All cells were recovered 24 or 48 hr after transfection. Percent
CAACTTT (320 bp product). Neurofilament light chain:GTCTTAATT
cell death was taken as the ratio of trypan blue-positive cells relative
GCTAACCA and CCCCTCTTTATGCAGAGT (220 bp product).
to total cell number in four independent experiments (Okazawa et
al., 1996a).
Two-Hybrid Deletion Assays
Immunoprecipitation of Cell Lines PQBP-1 cDNAs were amplified with PCR and subcloned between
1  107 cells were harvested 12 hr post transfection with AT30 or EcoRI and XhoI sites of the pEG202. The N-terminal primer was
AT82, incubated at 4C for 10 min in 1 ml TNE lysis buffer (10 mM AAAGAATTCATGCCGCTGCCCGTTGCG and the C-terminal prim-
Tris-HCl (pH 7.8), 1% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM ers were m1, AAACTCGAGCAACCTGGTGGCCTCGTA; m2, AAACT
PMSF, 10 g/ml leupeptin, and 10 g/ml aprotinin), and disrupted CGAGCAACTTTTCTTCAGCATC; m3, AAACTCGAGAGACTTGTCG
by trituration through a 21-gauge needle. Cellular debris was re- TGGCCCCG; m4, AAACTCGAGTTCTTTGCCCTCTTCCCG; and m5,
moved by centrifugation at 10,000 g for 10 min. Supernatant was AAACTCGAGCTTCTTGCTCTTGGGATA. m1, m2, m3, m4, and m5
preincubated with protein G-agarose (Oncogene Science) for 1 hr contain aa 1–45, 1–103, 1–138, 1–175, and 1–192 of PQBP-1, respec-
at 4C. 2 l of C2 or anti-ataxin-1 polyclonal antibody (Servadio et tively. They were cotransfected with the prey and reporter plasmids,
al., 1995) was added to the supernatant, incubated for 1 hr at 4C, incubated on Glu/CM/HIs()Trp()Ura() (SD-HWU) plates, and se-
and precipitated with protein G-agarose. The beads were washed lected on Gal/CM/HIs()Trp()Ura()Leu() (SG-HWUL) and Gal/
extensively with TNE buffer four times. Precipitates were subjected CM/His()Trp()Ura()X-gal (SG-HWUX-gal) plates.
to 15% SDS PAGE, blotted with anti-ataxin-1 or C2 diluted 1:2000
in PBS (5% Tween 20), and detected with the ECL system (Amer-
sham). For characterization of high-molecular weight ladder bands CAT Assays
of PQBP-1, anti-ubiquitin antibody (DAKO) was used. Anti-EGFP 1  106 P19 or S7 cells were cultured in -MEM medium (Sigma)
antibody (Clontech) was used for IP using PQBP1-EGFP and with 10% fetal bovine serum in 10 cm dishes (Corning) and trans-
PQBP1-EGFP. fected with 20 to 40 g plasmids using Superfect (Qiagen). 24 hr
post transfection, cells were collected in 0.25 M Tris-HCl (pH 7. 4)
Immunoprecipitation with Ataxin-1 Transgenic Mouse Brain and extracted by repeating freeze/thaw. CAT reaction was per-
For IP with mice tissue, 200 mg of cerebellar cortex from 6-month- formed after appropriate adjustment of extract quantities as de-
old transgenic mice and littermates were suspended in 1 ml of TNE scribed previously (Okamoto et al., 1990).
buffer and precipitated as described for cell IPs. Anti-QM antibody
was purchased from Santa Cruz. Transgenics express full-length
SCA1 with 82 CAG repeats under the Purkinje cell-specific promoter Immunohistochemistry
of Pcp2 gene (B05, Lin et al., 2000). The brain from a SCA1 patient (73-yr-old female; 78 repeats) was
fixed in formaldehyde 24 hr after death, and cerebellar tissues were
embedded in paraffin. 40 m sections were deparaffinized, stainedPull-Down Assays
GST-PQBP-1 fusion constructs containing the full-length or the WW with C2 at 1:200 dilution, then visualized with 0.05% 3,3-diamino-
benzidine tetrahydrochloride and 0.01% H2O2 in 50 mM Tris (pH 7.6).domain of PQBP-1 (GST-PQBP1-F and GST-PQBP1-WW, respec-
tively) were prepared by subcloning the following cDNAs into Paraffin sections were briefly counterstained with hematoxylin and
eosin. To exclude false-positive staining, control experiments werepGEX4T-1 or pGEX-2TK (Pharmacia). For GST-PQBP1-full, cDNA
was amplified using F:AAAGAATTCATGCCGCTGCCCGTTGCG and performed with normal rabbit serum in place of primary antibody,
which showed no staining (data not shown).T7 primers (Staratagene) from the original pBSSK-PQBP-1 plas-
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